Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prophylactic Ketamine Attenuates Learned Fear.

McGowan JC, LaGamma CT, Lim SC, Tsitsiklis M, Neria Y, Brachman RA, Denny CA.

Neuropsychopharmacology. 2017 Jul;42(8):1577-1589. doi: 10.1038/npp.2017.19. Epub 2017 Jan 27.

2.

Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy Against Stress-Induced Depressive-like Behavior.

Mastrodonato A, Martinez R, Pavlova IP, LaGamma CT, Brachman RA, Robison AJ, Denny CA.

Biol Psychiatry. 2018 Dec 1;84(11):846-856. doi: 10.1016/j.biopsych.2018.02.011. Epub 2018 Feb 23.

PMID:
29615190
3.

Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors.

Mastrodonato A, Cohensedgh O, LaGamma CT, McGowan JC, Hunsberger HC, Denny CA.

Behav Brain Res. 2019 Sep 26;378:112238. doi: 10.1016/j.bbr.2019.112238. [Epub ahead of print]

PMID:
31563463
4.

Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress.

McGowan JC, Hill C, Mastrodonato A, LaGamma CT, Kitayev A, Brachman RA, Narain NR, Kiebish MA, Denny CA.

Neuropsychopharmacology. 2018 Aug;43(9):1813-1821. doi: 10.1038/s41386-018-0043-7. Epub 2018 Mar 29.

5.

Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.

Brachman RA, McGowan JC, Perusini JN, Lim SC, Pham TH, Faye C, Gardier AM, Mendez-David I, David DJ, Hen R, Denny CA.

Biol Psychiatry. 2016 May 1;79(9):776-786. doi: 10.1016/j.biopsych.2015.04.022. Epub 2015 May 4.

6.

Prophylactic efficacy of 5-HT4R agonists against stress.

Chen BK, Mendez-David I, Luna VM, Faye C, Gardier AM, David DJ, Denny CA.

Neuropsychopharmacology. 2019 Oct 10. doi: 10.1038/s41386-019-0540-3. [Epub ahead of print]

PMID:
31600767
7.

Ketamine administration diminishes operant responding but does not impair conditioned fear.

Groeber Travis CM, Altman DE, Genovese RF.

Pharmacol Biochem Behav. 2015 Dec;139(Pt A):84-91. doi: 10.1016/j.pbb.2015.10.013. Epub 2015 Oct 23.

PMID:
26526065
8.

Extinction-induced "despair" in the water maze, exploratory behavior and fear: effects of chronic antidepressant treatment.

Schulz D, Buddenberg T, Huston JP.

Neurobiol Learn Mem. 2007 May;87(4):624-34. Epub 2007 Jan 16.

PMID:
17223365
9.

NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.

Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, Kelley KW, Dantzer R.

Neuropsychopharmacology. 2013 Aug;38(9):1609-16. doi: 10.1038/npp.2013.71. Epub 2013 Mar 19.

10.

Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials.

Amann LC, Halene TB, Ehrlichman RS, Luminais SN, Ma N, Abel T, Siegel SJ.

Neurobiol Dis. 2009 Aug;35(2):311-7. doi: 10.1016/j.nbd.2009.05.012. Epub 2009 May 23.

11.

Ketamine accelerates fear extinction via mTORC1 signaling.

Girgenti MJ, Ghosal S, LoPresto D, Taylor JR, Duman RS.

Neurobiol Dis. 2017 Apr;100:1-8. doi: 10.1016/j.nbd.2016.12.026. Epub 2016 Dec 30.

12.

Antidepressant but Not Prophylactic Ketamine Administration Alters Calretinin and Calbindin Expression in the Ventral Hippocampus.

LaGamma CT, Tang WW, Morgan AA, McGowan JC, Brachman RA, Denny CA.

Front Mol Neurosci. 2018 Nov 6;11:404. doi: 10.3389/fnmol.2018.00404. eCollection 2018.

13.

Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis.

Honsberger MJ, Taylor JR, Corlett PR.

Schizophr Res. 2015 May;164(1-3):227-33. doi: 10.1016/j.schres.2015.02.009. Epub 2015 Feb 24.

14.

N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.

Lin JC, Chan MH, Lee MY, Chen YC, Chen HH.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:7-13. doi: 10.1016/j.pnpbp.2016.06.002. Epub 2016 Jun 10.

PMID:
27296677
15.

Ketamine Alleviates Fear Generalization Through GluN2B-BDNF Signaling in Mice.

Asim M, Hao B, Yang YH, Fan BF, Xue L, Shi YW, Wang XG, Zhao H.

Neurosci Bull. 2019 Aug 23. doi: 10.1007/s12264-019-00422-4. [Epub ahead of print]

PMID:
31444653
16.

High-dose corticosterone after fear conditioning selectively suppresses fear renewal by reducing anxiety-like response.

Wang H, Xing X, Liang J, Bai Y, Lui Z, Zheng X.

Pharmacol Biochem Behav. 2014 Sep;124:188-95. doi: 10.1016/j.pbb.2014.06.003. Epub 2014 Jun 14.

PMID:
24933336
17.

Methylphenidate enhances extinction of contextual fear.

Abraham AD, Cunningham CL, Lattal KM.

Learn Mem. 2012 Jan 17;19(2):67-72. doi: 10.1101/lm.024752.111. Print 2012 Feb.

18.

Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine.

Duclot F, Perez-Taboada I, Wright KN, Kabbaj M.

Neuropharmacology. 2016 Oct;109:293-305. doi: 10.1016/j.neuropharm.2016.06.022. Epub 2016 Jun 22.

19.

No Sex-Specific Differences in the Acute Antidepressant Actions of (R)-Ketamine in an Inflammation Model.

Chang L, Toki H, Qu Y, Fujita Y, Mizuno-Yasuhira A, Yamaguchi JI, Chaki S, Hashimoto K.

Int J Neuropsychopharmacol. 2018 Oct 1;21(10):932-937. doi: 10.1093/ijnp/pyy053.

20.

Cannabinoid modulation of chronic mild stress-induced selective enhancement of trace fear conditioning in adolescent rats.

Reich CG, Iskander AN, Weiss MS.

J Psychopharmacol. 2013 Oct;27(10):947-55. doi: 10.1177/0269881113499207. Epub 2013 Aug 7.

Supplemental Content

Support Center